Miguel Ángel Seguí

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers

Roy R. L. Bastien, Álvaro Rodríguez-Lescure, Mark Ebbert et al. · BMC Medical Genomics · 2012 · 336 citations · Full text

Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Miguel Martín, Álvaro Rodríguez-Lescure, A. Ruiz et al. · JNCI Journal of the National Cancer Institute · 2008 · 238 citations · Full text

Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer

Miguel Martín, Miguel Ángel Seguí, Antonio Antón et al. · New England Journal of Medicine · 2010 · 208 citations · Full text

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

Miguel Martín, Aňa Lluch, Miguel Ángel Seguí et al. · Annals of Oncology · 2006 · 204 citations · Full text

Breast Oncology, Breast Cancer Patients, Medicine +8

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study

Emilio Alba, José Ignacio Chacón, Aňa Lluch et al. · Breast Cancer Research and Treatment · 2012 · 143 citations · Full text

Neoadjuvant Setting, Oncology, Breast Oncology +10